Pre-Service Teachers Awareness of Using WhatsApp as a Pedagogical Tool for The Practicum Program During Coved-19 Pandemic

This study explored the extent to which pre-service teachers were aware of using WhatsApp effectively as a pedagogical tool for educational purposes during the Covid-19 pandemic. Due to the COVID-19 pandemic outbreak, Saudi Arabias education system switched to distance learning; accordingly, there was a growing reliance on information and communication technology (ICT) for online teaching and learning. Furthermore, the increased use of social networks such as WhatsApp could have many benefits and consequences on students’ learning. Twenty-six female preservice teachers (PSTs) made a WhatsApp group to collaborate with their peers for eight weeks during the Covid-19 pandemic. Each week, the PSTs were required to share a minimum of three posts for a total of twenty-four posts. The instructions given to the PSTs focused on sharing useful posts related to their practicum program. A mixed-method research design was used for this study. First, quantitative data were collected by recording the frequency and range of posts to determine the amount of participation. Second, the qualitative data were gathered by conducting focus group interviews to understand the reasons behind each PST’s participation. Findings revealed that the contribution rate of the entire group was high (77%), with 20 PSTs meeting the minimum required number of posts. Remarkably, these 20 PSTs formed a unique norm of the learning community by regulating their own and other peers’ works as well. Only six pre-service teachers did not meet the required number of useful posts. The reasons behind the contributions, more findings, and further research suggestions and recommendations for educational settings are discussed

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Whole-genome sequencing reveals host factors underlying critical COVID-19

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2,3,4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease

Report of the SUGRA Working Group for Run II of the Tevatron

We present an analysis of the discovery reach for supersymmetric particles at the upgraded Tevatron collider, assuming that SUSY breaking results in universal soft breaking parameters at the grand unification scale, and that the lightest supersymmetric particle is stable and neutral. We first present a review of the literature, including the issues of unification, renormalization group evolution of the supersymmetry breaking parameters and the effect of radiative corrections on the effective low energy couplings and masses of the theory. We consider the experimental bounds coming from direct searches and those arising indirectly from precision data, cosmology and the requirement of vacuum stability. The issues of flavor and CP-violation are also addressed. The main subject of this study is to update sparticle production cross sections, make improved estimates of backgrounds, delineate the discovery reach in the supergravity framework, and examine how this might vary when assumptions about universality of soft breaking parameters are relaxed. With 30 fb$^{-1}$ luminosity and one detector, charginos and neutralinos, as well as third generation squarks, can be seen if their masses are not larger than 200-250 GeV, while first and second generation squarks and gluinos can be discovered if their masses do not significantly exceed 400 GeV. We conclude that there are important and exciting physics opportunities at the Tevatron collider, which will be significantly enhanced by continued Tevatron operation beyond the first phase of Run II.We present an analysis of the discovery reach for supersymmetric particles at the upgraded Tevatron collider, assuming that SUSY breaking results in universal soft breaking parameters at the grand unification scale, and that the lightest supersymmetric particle is stable and neutral. We first present a review of the literature, including the issues of unification, renormalization group evolution of the supersymmetry breaking parameters and the effect of radiative corrections on the effective low energy couplings and masses of the theory. We consider the experimental bounds coming from direct searches and those arising indirectly from precision data, cosmology and the requirement of vacuum stability. The issues of flavor and CP-violation are also addressed. The main subject of this study is to update sparticle production cross sections, make improved estimates of backgrounds, delineate the discovery reach in the supergravity framework, and examine how this might vary when assumptions about universality of soft breaking parameters are relaxed. With 30 fb$^{-1}$ luminosity and one detector, charginos and neutralinos, as well as third generation squarks, can be seen if their masses are not larger than 200-250 GeV, while first and second generation squarks and gluinos can be discovered if their masses do not significantly exceed 400 GeV. We conclude that there are important and exciting physics opportunities at the Tevatron collider, which will be significantly enhanced by continued Tevatron operation beyond the first phase of Run II

Accelerated surgery versus standard care in hip fracture (HIP ATTACK) : an international, randomised, controlled trial

Background: Observational studies have suggested that accelerated surgery is associated with improved outcomes in patients with a hip fracture. The HIP ATTACK trial assessed whether accelerated surgery could reduce mortality and major complications. Methods: HIP ATTACK was an international, randomised, controlled trial done at 69 hospitals in 17 countries. Patients with a hip fracture that required surgery and were aged 45 years or older were eligible. Research personnel randomly assigned patients (1:1) through a central computerised randomisation system using randomly varying block sizes to either accelerated surgery (goal of surgery within 6 h of diagnosis) or standard care. The coprimary outcomes were mortality and a composite of major complications (ie, mortality and non-fatal myocardial infarction, stroke, venous thromboembolism, sepsis, pneumonia, life-threatening bleeding, and major bleeding) at 90 days after randomisation. Patients, health-care providers, and study staff were aware of treatment assignment, but outcome adjudicators were masked to treatment allocation. Patients were analysed according to the intention-to-treat principle. This study is registered at ClinicalTrials.gov (NCT02027896). Findings: Between March 14, 2014, and May 24, 2019, 27 701 patients were screened, of whom 7780 were eligible. 2970 of these were enrolled and randomly assigned to receive accelerated surgery (n=1487) or standard care (n=1483). The median time from hip fracture diagnosis to surgery was 6 h (IQR 4\u20139) in the accelerated-surgery group and 24 h (10\u201342) in the standard-care group (p<0\ub70001). 140 (9%) patients assigned to accelerated surgery and 154 (10%) assigned to standard care died, with a hazard ratio (HR) of 0\ub791 (95% CI 0\ub772 to 1\ub714) and absolute risk reduction (ARR) of 1% ( 121 to 3; p=0\ub740). Major complications occurred in 321 (22%) patients assigned to accelerated surgery and 331 (22%) assigned to standard care, with an HR of 0\ub797 (0\ub783 to 1\ub713) and an ARR of 1% ( 122 to 4; p=0\ub771). Interpretation: Among patients with a hip fracture, accelerated surgery did not significantly lower the risk of mortality or a composite of major complications compared with standard care. Funding: Canadian Institutes of Health Research